Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 6.92% is 73% below its 5-year average of 25.30%, near the low end of its 5-year range (5.80%–57.94%).
6.74% below its 12-month average of 7.42%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): 1.67%.
RETURN ON ASSETS (ROA)
6.92%
RETURN ON ASSETS (ROA) AVG TTM
7.42%
RETURN ON ASSETS (ROA) AVG 3Y
10.30%
RETURN ON ASSETS (ROA) AVG 5Y
25.30%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.74%
CURRENT VS 3Y AVG
-32.85%
CURRENT VS 5Y AVG
-72.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
+122.54%
vs the sector median at left
Embecta Corp.
Market Cap
$357.28M
Return on Assets (ROA)
6.92%
TTM Avg
7.42%
3Y Avg
10.30%
5Y Avg
25.30%
Market Cap
$355.18M
Return on Assets (ROA)
-21.30%
TTM Avg
-29.99%
3Y Avg
-30.23%
5Y Avg
-24.37%
Market Cap
$355.92M
Return on Assets (ROA)
-24.64%
TTM Avg
-45.98%
3Y Avg
-40.55%
5Y Avg
-44.33%
Market Cap
$355.58M
Return on Assets (ROA)
-28.27%
TTM Avg
-117.81%
3Y Avg
-109.90%
5Y Avg
-91.03%
Market Cap
$356.58M
Return on Assets (ROA)
-4.29%
TTM Avg
-7.44%
3Y Avg
-40.66%
5Y Avg
-49.61%
Market Cap
$352.10M
Return on Assets (ROA)
-51.02%
TTM Avg
-63.00%
3Y Avg
-53.19%
5Y Avg
-73.16%
Market Cap
$362.81M
Return on Assets (ROA)
-65.87%
TTM Avg
-110.74%
3Y Avg
-99.78%
5Y Avg
-89.00%
Market Cap
$364.53M
Return on Assets (ROA)
-115.75%
TTM Avg
-127.38%
3Y Avg
-59.19%
5Y Avg
-98.90%
Market Cap
$374.87M
Return on Assets (ROA)
-24.06%
TTM Avg
-44.34%
3Y Avg
-68.40%
5Y Avg
-50.78%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $357.28M | 6.92% | 7.42% | 10.30% | 25.30% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $355.18M | -21.30% | -29.99% | -30.23% | -24.37% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.92M | -24.64% | -45.98% | -40.55% | -44.33% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $355.58M | -28.27% | -117.81% | -109.90% | -91.03% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.58M | -4.29% | -7.44% | -40.66% | -49.61% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $352.10M | -51.02% | -63.00% | -53.19% | -73.16% |
| Ocugen, Inc. (OCGN)vs › | $362.81M | -65.87% | -110.74% | -99.78% | -89.00% |
| Opus Genetics, Inc. (IRD)vs › | $364.53M | -115.75% | -127.38% | -59.19% | -98.90% |
| Canopy Growth Corporation (CGC)vs › | $374.87M | -24.06% | -44.34% | -68.40% | -50.78% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $376.04M | -41.58% | -23.89% | -13.16% | -19.94% |
ROA
6.9%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | 8.75% |
| 2024-09-30 | 6.09% |
| 2023-09-30 | 5.80% |
| 2022-09-30 | 20.58% |
| 2021-09-30 | 52.64% |
| 2020-09-30 | 57.94% |
| 2019-09-30 | 57.99% |
